undamentalytics Newsletter
Sign in

China Pharma Holdings, Inc. cash flow statement

In fiscal 2025, China Pharma Holdings, Inc.'s operations generated $148,261 of cash; it spent $59,324 on capital projects, leaving free cash flow of $88,937.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations8549633121−0−0−0−1−00−0
Depreciation and amortisation21122433333333322
Stock-based pay0000—————————————
Capital spending−0−0−0−195−100001000000
Free cash flow86427143120−1−1−1−1−00−0
Free cash flow after stock pay85427—————————————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CPHI vs TXMDCPHI vs EYPTCPHI vs NTRB

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from China Pharma Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to China Pharma Holdings, Inc.